AbbVie claims Phase 3 win for multiple myeloma drug etentamig

AbbVie said its T cell engager etentamig cut the risk of disease progression or death by 60% compared with standard therapies in a Phase 3 multiple myeloma trial. The Chicago-area company is now planning to ...